References
- Claudepierre P, Wendling D, Breban M, et al. Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what’s in a name? Joint Bone Spine 2012;79:534-5
- Wendling D, Guillot X, Prati C. The IL-23/Th 17 pathway in spondyloarthritis: The royal road? Joint Bone Spine 2015;82:1-4
- Wendling D, Claudepierre P, Prati C. Early diagnosis and management are crucial in spondyloarthritis. Joint Bone Spine 2013;80:582-5
- Wendling D, Lukas C, Paccou J, et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine 2014;81:6-14
- Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6-16
- Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis 2014;73:238-42
- Sieper J. How to define remission in ankylosing spondylitis? Ann Rheum Dis 2012;71(Suppl 2):i93-5
- Godfrin-Valnet M, Puyraveau M, Wendling D. Remission thresholds in spondyloarthritis: a prospective study in current practice. J Rheumatol 2014;41:617-18
- Godfrin-Valnet M, Puyraveau M, Prati C, Wendling D. Flare in spondyloarthritis: Thresholds of disease activity variations. Joint Bone Spine 2015. [Epub ahead of print]
- Claudepierre P. Spondyloarthritis: a window of opportunity? Joint Bone Spine 2014;81:197-9
- Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013;72:23-8
- Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther 2014;16:109
- Dougados M, d’Agostino MA, Benessiano J, et al. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine 2011;78:598-603
- Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014;73:817-23
- Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1705-13
- Baeten DL, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Arthritis Rheumatol 2014;66(Suppl):S360